Quick Answer
STRATA Skin Sciences, Inc. reported Cash and Equivalents of $7.91 million for fiscal year 2025.
STRATA Skin Sciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $7.91M | +9.0% |
| 2024 | $7.26M | +7.0% |
| 2023 | $6.78M | +24.8% |
| 2022 | $5.43M | -56.8% |
| 2021 | $12.59M | +18.7% |
| 2020 | $10.60M | +30.4% |
| 2019 | $8.13M | -50.7% |
| 2018 | $16.49M | +3.8% |
| 2018 | $15.89M | +10.0% |
| 2018 | $14.45M | +322.7% |
| 2018 | $3.42M | -16.0% |
| 2017 | $4.07M | +30.1% |
| 2017 | $3.13M | -20.6% |
| 2017 | $3.94M | +4.7% |
| 2017 | $3.76M | -4.2% |
| 2016 | $3.93M | +18.9% |
| 2015 | $3.30M | -71.1% |
| 2014 | $11.43M | +202.2% |
| 2013 | $3.78M | -51.9% |
| 2012 | $7.86M | -71.9% |
| 2011 | $28.00M | -8.3% |
| 2010 | $30.52M | +2.9% |
| 2009 | $29.67M | +96.9% |
| 2008 | $15.07M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.08M | +0.2% | +18.6% |
| June 30, 2025 | $5.97M | +8.8% | -8.4% |
| March 31, 2025 | $6.51M | +24.3% | -10.3% |
| December 31, 2024 | $7.26M | +7.0% | +2.8% |
| September 30, 2024 | $7.06M | -1.0% | +28.8% |
| June 30, 2024 | $5.48M | -39.3% | +4.7% |
| March 31, 2024 | $5.24M | +85.4% | -22.8% |
| December 31, 2023 | $6.78M | +24.8% | -4.9% |
- STRATA Skin Sciences, Inc. showed an increase of +9.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, STRATA Skin Sciences, Inc.’s cash and equivalents has declined by 47.5% (from $15.07 million to $7.91 million).
- The most recent figure is from STRATA Skin Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: